Immediate n = 44 | Conservative n = 43 | p value | |
---|---|---|---|
Days alive without AT by day 28, median [IQR] | 16.0 [0.0–20.0] | 18.0 [0.0–21.0] | 0.50 |
Days alive without broad-spectrum AT by day 28, median [IQR] | 23.5 [5.0–26.0] | 25.0 [0.0–28.0] | 0.53 |
Days alive without carbapenem by day 28, median [IQR] | 28.0 [9.0–28.0] | 28.0 [0.0–28.0] | 0.65 |
iMV duration, days, median [95% confidence interval] HR [95%CI] | 9.0 [6.0–24.0] 1.1 [0.7–1.8] | 9.0 [6.0–19.0] | 0.65 |
Ventilator-free days, median [IQR] | 18.5 [0.0–23.0] | 16.0 [0.0–22.0] | 0.99 |
ICU stay, days, median [95% confidence interval] | 9.0 [6.0–14.0] | 13.0 [8.0–17.0] | 0.71 |
Day-28 mortality, n (%) HR [95%CI] | 11 (25.0) 0.8 [0.4–2.0] | 11 (25.6) | 0.71 |
VAP-related abscess, n (%) | 0 | 2 (4.6) | 0.24 |
VAP-related bacteraemia, n (%) | 0 | 2 (4.6) | 0.24 |
Subsequent VAP, n (%) | |||
Recurrencea | 3 (6.8) | 2 (4.6) | 0.11 |
Superinfectiona | 2 (4.5) | 0 (0) | |
First VAP after suspected unconfirmed VAP | 0 (0) | 4 (9.3) | |
MRBb, n (%) | 0 | 0 | - |
Clostridium difficile infections, n (%) | 0 | 0 | - |
Antibiotic allergy, n (%) | 2 (4.5) | 0 | 0.49 |